Over the last month, Dell and Super Micro have been sparring in the headlines with new product releases. Just two weeks ago, ...

The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent company ...

For adolescents, weight loss after bariatric surgery was durable out to 10 years, data from the Teen Longitudinal Assessment ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.

Roche later made changes to the trial design, although the company said overall results support further testing.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like ...